Systemic sclerosis
Determinants of Morbidity and Mortality of Systemic Sclerosis in Canada

https://doi.org/10.1016/j.semarthrit.2008.06.002Get rights and content

Objectives

To describe the morbidity and mortality in Canadian scleroderma (SSc) patients focusing on gender, SSc type, and organ-specific prognosis in a cohort of patients seen from 1994 to 2004 in a Southwestern Ontario SSc clinic. We also compared this cohort to data from the literature, which showed that mean survival in recent studies has risen to 72 months versus 48 months in earlier studies.

Methods

This was a cohort study of all SSc patients followed at 1 rheumatology center. Data were abstracted by chart review and entered into a database. The demographic and clinical characteristics of SSc patients were compared between those who survived versus those who died over the 10-year follow-up period. Five- and 10-year survival rates were compared between cohort subsets (sex, diffuse/limited disease type, and organ involvement including the following: scleroderma renal crisis, interstitial lung disease (ILD), hypertension, cardiac, gastrointestinal involvement, pulmonary arterial hypertension, and antinuclear antibody positivity).

Results

One hundred eighty-five subjects (158 women), 63% with limited cutaneous SSc, were included. The mean disease duration until last visit or death was 9.1 years (7.9 years in diffuse and 9.8 years in limited). Although more women had either subtype, men were more likely to have diffuse cutaneous SSc (dcSSc) than women (67% of men had dcSSc versus 32% of women, P = 0.0009), and to have an earlier mean age of diagnosis (41.3 ± 2.8 years old versus 49.7 ± 1.2 years, P = 0.006). Overall mortality was 23%; 22% of men (n = 6) and 23% of women (n = 36) were deceased. The 5-year survival was 90% (95% for limited and 81% for diffuse) and the 10-year survival was 82% (92% for limited and 65% for diffuse). Deceased persons were more likely to have had dcSSc (P = 0.03), cardiac disease (P < 0.0001), ILD (P = 0.006), gastrointestinal disease (P = 0.01), and systemic hypertension (P = 0.009). Four of 13 patients with scleroderma renal crisis died. Survival analyses demonstrated that persons with dcSSc (P = 0.001), cardiac disease (P < 0.0001), and hypertension (P = 0.01) had worse survival rates than their counterparts without these disorders. The primary cause of death was ascertained for 33 of the 42 deceased individuals and included the following: pulmonary arterial hypertension (n = 5), renal complications (n = 9), ILD (n = 10), and cardiac complications (n = 9). There appears to be a trend toward longer survival of scleroderma patients over the past few decades.

Conclusions

We conclude that cardiac involvement, dcSSc, and hypertension are associated with worse survival, and survival of patients with scleroderma is improving compared with older reports in the literature.

Section snippets

Study Design

This was a cohort study. Demographic and clinical characteristics of SSc patients were compared between those who survived versus those who died during follow-up in a rheumatology SSc practice between 1994 and 2004.

Data Collection

The database was constructed using the medical records of patients with a diagnosis of SSc who met preliminary American College of Rheumatology criteria (19), or who had CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasia) (20).

Results

One hundred eighty-five patients were included in the analysis (158 women and 27 men). Thirty-seven percent of the patients had dcSSc and 63% had lcSSc (Table 1). At the time of analysis, the mean follow-up time until death or last visit was 9.1 years (similar between those living and those deceased) (Table 2), and 23% of the total cohort were deceased. Thirty-seven percent were smokers and another 9% had been past smokers. The 5-year survival was 90% (95% for limited and 81% for diffuse) and

Demographic Characteristics

The sex-specific differences observed in our scleroderma cohort were consistent with the published literature, in which men had earlier age of disease onset (3), a greater likelihood of having dcSSc (3, 21), and an earlier average age of death (3, 13). Age at diagnosis was only slightly younger for those with dcSSc compared with lcSSc, and this may reflect a trend for increased early detection of lcSSc, as historically lcSSc has been thought to onset later than dcSSc.

Mortality in SSc

We compared our data to 2

References (48)

  • A.J. Silman

    Scleroderma—demographics and survival

    J Rheumatol

    (1997)
  • M.D. Mayes et al.

    Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population

    Arthritis Rheum

    (2003)
  • M. Abu-Shakra et al.

    Mortality in systemic sclerosis: a comparison with the general population

    J Rheumatol

    (1995)
  • R.D. Altman et al.

    Predictors of survival in systemic sclerosis (scleroderma)

    Arthritis Rheum

    (1991)
  • T.A. Medsger et al.

    Epidemiology of systemic sclerosis (scleroderma)

    Ann Intern Med

    (1971)
  • V. Steen et al.

    Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors

    Ann Intern Med

    (1990)
  • L. Scussel-Lonzetti et al.

    Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival

    Medicine (Baltimore)

    (2002)
  • A.J. Barnett et al.

    A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease

    J Rheumatol

    (1988)
  • V.D. Steen et al.

    Severe organ involvement in systemic sclerosis with diffuse scleroderma

    Arthritis Rheum

    (2000)
  • B.J. Harrison et al.

    Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis

    Arthritis Rheum

    (2002)
  • M. Kuwana et al.

    Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis

    Arthritis Rheum

    (1994)
  • Preliminary criteria for the classification of systemic sclerosis (scleroderma)

    Arthritis Rheum

    (1980 May)
  • E.C. LeRoy et al.

    Scleroderma (systemic sclerosis): classification, subsets and pathogenesis

    J Rheumatol

    (1988)
  • C. Ferri et al.

    Cutaneous and serologic subsets of systemic sclerosis

    J Rheumatol

    (1991)
  • Cited by (175)

    View all citing articles on Scopus

    This research was funded in part by the University of Western Ontario Summer Research Training Program (SRTP) grant.

    View full text